Morgan Stanley’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Morgan Stanley’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-181,582	Closed	-$735K	–	8089
2023 Q4	$735K	Buy	181,582 +143,012	+371%	+$436K	﹤0.01%	5450
2023 Q3	$104K	Sell	38,570 -1,407	-4%	-$5.51K	﹤0.01%	5875
2023 Q2	$373K	Sell	39,977 -1,910	-5%	-$18.8K	﹤0.01%	5364
2023 Q1	$372K	Buy	41,887 +30,409	+265%	+$298K	﹤0.01%	5423
2022 Q4	$57.2K	Buy	11,478 +2,721	+31%	+$15.9K	﹤0.01%	6235
2022 Q3	$51K	Sell	8,757 -3,876	-31%	-$27.4K	﹤0.01%	6401
2022 Q2	$70K	Buy	12,633 +2,985	+31%	+$24.7K	﹤0.01%	6451
2022 Q1	$111K	Sell	9,648 -31	-0.3%	-$331	﹤0.01%	6244
2021 Q4	$123K	Buy	+9,679	New	+$146K	﹤0.01%	6318

Morgan Stanley's THRX Position: Q1 2024 in Review

Morgan Stanley sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 181,582 shares — an estimated $735K sold.

Morgan Stanley first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $735K in Q4 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

Morgan Stanley reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Morgan Stanley sold 181,582 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $735K.
Morgan Stanley first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Morgan Stanley's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $735K in Q4 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.